Literature DB >> 3159530

Multiple-dose ciprofloxacin dose ranging and kinetics.

M A Gonzalez, A H Moranchel, S Duran, A Pichardo, J L Magana, B Painter, G L Drusano.   

Abstract

We injected multiple doses of intravenous ciprofloxacin over 10 minutes every 12 hours for 1 week to nine healthy subjects, while three other subjects received placebo. Ciprofloxacin doses of 25, 50, and 75 mg were evaluated with a 1-week washout between each dose level. Mean (+/- SD) terminal excretion t1/2S were 3.56 +/- 0.66, 4.15 +/- 0.68, and 3.46 +/- 0.42 hours for the 25, 50, and 75 mg doses. Serum clearances were 35.4 +/- 6.8, 31.8 +/- 3.0, and 31.3 +/- 5.4 L/hr/1.73 m2 for these doses. Urine concentrations remained above the minimal inhibitory concentration of most urinary tract pathogens for the full 12-hour dosing interval at each dose. Renal clearance accounted for 65% to 70% of the serum clearance, but because biologically active renally excreted metabolites have been identified, our values exceed the true values. The doses of ciprofloxacin we intravenously injected were well tolerated and appeared adequate for treatment of urinary tract infections. For serious hospital-acquired sepsis, however, larger doses should be evaluated.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3159530     DOI: 10.1038/clpt.1985.102

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  9 in total

Review 1.  Pharmacokinetic considerations for antimicrobial therapy in patients receiving renal replacement therapy.

Authors:  Federico Pea; Pierluigi Viale; Federica Pavan; Mario Furlanut
Journal:  Clin Pharmacokinet       Date:  2007       Impact factor: 6.447

2.  Pharmacokinetics of ciprofloxacin in the human eye: a clinical study and population pharmacokinetic analysis.

Authors:  N Morlet; G G Graham; B Gatus; A J McLachlan; C Salonikas; D Naidoo; I Goldberg; C M Lam
Journal:  Antimicrob Agents Chemother       Date:  2000-06       Impact factor: 5.191

Review 3.  Clinical pharmacokinetics of ciprofloxacin.

Authors:  K Vance-Bryan; D R Guay; J C Rotschafer
Journal:  Clin Pharmacokinet       Date:  1990-12       Impact factor: 6.447

Review 4.  Quinolones in the elderly.

Authors:  T Bergan
Journal:  Drugs       Date:  1995       Impact factor: 9.546

5.  Altered pharmacokinetic disposition of ciprofloxacin and vancomycin after single and multiple doses in rabbits.

Authors:  S L Barriere; G W Kaatz; D R Schaberg; R Fekety
Journal:  Antimicrob Agents Chemother       Date:  1987-07       Impact factor: 5.191

Review 6.  Ciprofloxacin. A review of its antibacterial activity, pharmacokinetic properties and therapeutic use.

Authors:  D M Campoli-Richards; J P Monk; A Price; P Benfield; P A Todd; A Ward
Journal:  Drugs       Date:  1988-04       Impact factor: 9.546

Review 7.  Clinical pharmacokinetics and pharmacodynamics of tigecycline.

Authors:  April Barbour; Stephan Schmidt; Benjamin Ma; Lars Schiefelbein; Kenneth H Rand; Olaf Burkhardt; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2009       Impact factor: 6.447

8.  Ciprofloxacin versus vancomycin in the therapy of experimental methicillin-resistant Staphylococcus aureus endocarditis.

Authors:  G W Kaatz; S L Barriere; D R Schaberg; R Fekety
Journal:  Antimicrob Agents Chemother       Date:  1987-04       Impact factor: 5.191

Review 9.  A Physiologically-Based Pharmacokinetic Model to Describe Ciprofloxacin Pharmacokinetics Over the Entire Span of Life.

Authors:  Jan-Frederik Schlender; Donato Teutonico; Katrin Coboeken; Katrin Schnizler; Thomas Eissing; Stefan Willmann; Ulrich Jaehde; Heino Stass
Journal:  Clin Pharmacokinet       Date:  2018-12       Impact factor: 6.447

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.